AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Mar 20, 2024
OCALA, Fla., March 20, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM...
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Mar 15, 2024
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ETOCALA, Fla., March 15, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that it will present at the Virtual...
AIM ImmunoTech Announces Launch of CEO Corner Platform
Mar 7, 2024
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future videos Access the AIM CEO Corner Here! OCALA, Fla., March 07, 2024 --...
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Feb 29, 2024
Company continues progress across Ampligen® clinical development programs Growing body of promising data demonstrates Ampligen's potential to address multiple high-value indications OCALA, Fla., Feb. 29, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or...
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Feb 14, 2024
Phase 1b portion of the study expected to be completed within six monthsOCALA, Fla., Feb. 14, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the first subject has been dosed at Erasmus Medical Center ("Erasmus MC") in a Phase...
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
Feb 8, 2024
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions OCALA, Fla., Feb. 08, 2024 -- AIM ImmunoTech Inc....
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Jan 24, 2024
Subject enrollment is expected in Q1 2024OCALA, Fla., Jan. 24, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that it has received authorization from the Erasmus Medical Center ("Erasmus MC") Ethics Committee to open a...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
Jan 22, 2024
First enrollment takes place at Erasmus Medical Center in Rotterdam, NetherlandsOCALA, Fla., Jan. 22, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the first subject has been enrolled at Erasmus Medical Center ("Erasmus...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Jan 10, 2024
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla., Jan. 10, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the...
AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting
Jan 5, 2024
OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that shareholders have elected all four of the Company's directors, Stewart L. Appelrouth, Nancy K. Bryan, Thomas K. Equels and William M. Mitchell, at the Company's 2023...